SAREPTA

Class [005]
Pharmaceutical preparations, namely, oligonucleotide compounds gene transfer therapies, and gene editing therapies for use in targeted pharmaceutical therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, for treating loss of neurons, loss of nerves, muscle degeneration, and muscle weakness associated with neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; pharmaceutical preparations, namely, antisense oligonucleotides for therapeutic purposes based on morpholino oligomer technology platform; pharmaceutical preparations that modulate rna expression; gene therapy products, namely, gene delivery agents in the form of fluids used for the delivery of pharmaceuticals preparations; pharmaceutical preparations for gene therapy, gene editing, and genome editing; gene therapy products in the nature of injectable biologic preparations for treating loss of neurons, loss of nerves, muscle degeneration, and muscle weakness associated with neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; biological preparations for use in gene therapy containing genetic materials for protein expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; viruses, viral vectors and viral constructs for regulating, modifying or restricting protein expression for therapeutic purposes for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders